Advertisement


Bernd Kasper, MD, PhD, on Desmoid Tumors: Results on Nirogacestat vs Placebo

ESMO Congress 2022

Advertisement

Bernd Kasper, MD, PhD, of Germany’s Mannheim Cancer Center, discusses phase III data from the DeFi trial, the largest study conducted to date for patients with desmoid tumors. The trial showed that the gamma secretase inhibitor nirogacestat demonstrated improvements in all primary and secondary efficacy endpoints. Although considered benign because of their inability to metastasize, desmoid tumors can cause significant morbidity and, occasionally, mortality in patients (Abstract LBA2).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
It's my pleasure to speak about DeFi phase III trial of nirogacestat in progressing desmoid tumor patients and I had the pleasure to present that trial yesterday at ESMO 2022 in the presidential session. When talking about desmoid tumors, we are actually talking about a rare disease. They are locally aggressive and invasive soft tissue tumors that are somehow difficult to manage due to their variable presentations, the unpredictable clinical cause, and the lack of currently approved therapies. There is indeed a clear rationale for the use of gamma secretase inhibitors in this disease as desmoid tumors express [inaudible 00:00:47], which can be blocked by gamma secretase inhibitors. So nirogacestat is an investigational oral and selective small molecule gamma secretase inhibitor that already showed activity in phase I and II trials in desmoid tumors with a manageable safety profile. The phase III trial is a large global randomized double blind placebo-controlled trial, looking at safety, efficacy and tolerability of nirogacestat in comparison to placebo in resist progressing desmoid tumors. We actually randomized 142 patients in 37 sites all over the world and primary endpoint was progression-free survival and secondary endpoints included overall response rate, and a couple of different patient-reported outcome measures. So the results are as follows. The primary endpoint was met with improved progression-free survival, demonstrating a statistically significant 71% reduction in the risk of disease progression. And the confirmed objective response rate was 41% with nirogacestat as compared to 8% in the placebo arm. Again, highly statistically significant, including 7% complete responses with nirogacestat. The median time to response was 5.6 months with nirogacestat compared to 11 month in the placebo arm. In terms of safety, actually nirogacestat was well tolerated. 95% of all treatment emergent adverse events were grade I or II. The most frequent side effect with nirogacestat were diarrhea, rash, hyperphosphatemia and fatigue. And those reductions were necessary in about 40% of patients and were primarily due to diarrhea, rash, and stomatitis. In summary, DeFi represents the largest and most rigorous randomized controlled trial to-date in desmoid tumor. It actually definitely showed rapid, sustained and statistically significant improvements in all primary and secondary endpoints. It had a manageable safety profile with 95% of all the treatment emergent adverse events being grade I or II, and nirogacestat does have the potential to become the standard of care in desmoid tumors requiring systemic treatment. There are definitely a couple of open questions still from that trial. One question might be the lengths of treatment duration so there could be something like a discontinuation trial. But what we'd learned from that trial already that nirogacestat is absolutely feasible for long-term treatment in this patient population and we will investigate, of course, a lot of other questions as well.

Related Videos

Colorectal Cancer
Immunotherapy

Julien Taïeb, MD, PhD, on Colorectal Cancer: Recent Findings on Avelumab vs Standard Second-Line Chemotherapy

Julien Taïeb, MD, PhD, of Paris Descartes University, discusses phase II results from the SAMCO-PRODIGE 54 trial, which shows the efficacy and safety of avelumab in the second-line treatment of patients with deficient DNA mismatch–repair microsatellite-instability metastatic colorectal cancer. According to Dr. Taïeb, the study indirectly suggests this population should be treated as soon as possible with an immune checkpoint inhibitor (Abstract LBA23).

Gynecologic Cancers
Immunotherapy

Ana Oaknin, MD, PhD, on Cervical Cancer: Safety and Efficacy Results With Nivolumab and Ipilimumab

Ana Oaknin, MD, PhD, of Barcelona’s Vall d’Hebron University Hospital, discusses findings from the CheckMate 358 trial, which showed that chemotherapy-free immunotherapy with nivolumab alone or in combination with ipilimumab may provide durable tumor regression with manageable toxicity in patients with recurrent or metastatic cervical cancer, regardless of tumor PD-L1 expression (Abstract 520MO).

 

Skin Cancer
Immunotherapy

Sapna P. Patel, MD, on Melanoma: New Data on Pembrolizumab, Adjuvant vs Neoadjuvant Plus Adjuvant

Sapna P. Patel, MD, of The University of Texas MD Anderson Cancer Center, discusses the latest findings from the SWOG S1801 trial, which showed that using single-agent pembrolizumab as neoadjuvant therapy improved event-free survival compared to adjuvant therapy in high-risk resectable stage III–IV melanoma (Abstract LBA6).

Colorectal Cancer

Marinde J.G. Bond, PhD Candidate, on Colorectal Liver Metastases: FOLFOX/FOLFIRI, Bevacizumab, and Panitumumab

Marinde J.G. Bond, PhD Candidate, of the University Medical Center, Utrecht, discusses phase III findings from the CAIRO5 study of the Dutch Colorectal Cancer Group, the first such trial in defined subgroups of patients with initially unresectable colorectal cancer liver metastases and left-sided and RAS/BRAF V600E wild-type tumor. The study compared FOLFOX/FOLFIRI plus either bevacizumab or panitumumab (Abstract LBA21).

 

Kidney Cancer
Immunotherapy

Axel Bex, MD, PhD, on Renal Cell Carcinoma: Phase III Results With Atezolizumab as Adjuvant Therapy

Axel Bex, MD, PhD, of the Netherlands Cancer Institute, discusses phase III findings from the IMmotion010 study, which evaluated the efficacy and safety of atezolizumab vs placebo in patients with renal cell cancer who are at high risk of disease recurrence following nephrectomy (Abstract LBA66).

Advertisement

Advertisement




Advertisement